APC Multiplex Mutation Screening Kit

Adenomatous polyposis coli (APC) is widely accepted as a tumor suppressor gene highly mutated in colorectal cancers (CRC). Mutation and inactivation of this gene is a key and early event almost uniquely observed in colorectal tumorigenesis.

Cancer is a genetic disease with uncontrolled growth of abnormal cells. Some types of cancer are frequently associated with specific genetic mutations. Those mutations provide the biomarkers that allow more specific cancer treatments, known as targeted therapy.

Targeted therapy is a newer type of cancer treatment that offers patients the opportunity to use a drug that has a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. Therefore, it is a critical step towards targeted therapy by identifying the cancer mutations with a precise and sensitive method.